Market closed

Arvinas/$ARVN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Arvinas

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Ticker

$ARVN
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
New Haven, United States

Employees

445
Website
www.arvinas.com

Arvinas Metrics

BasicAdvanced
$1.2B
-
-$4.46
1.97
-

$1.2B

1.97

$53.08

$17.35

913K

4.166

4.119

0.119

0.256

-20.07%

-59.16%

7.739

2.11

2.11

-4.797

1.07%

-19.15%

92.41%

5.46%

What the Analysts think about Arvinas

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Arvinas stock.

Arvinas Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Arvinas Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Arvinas News

AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

Accesswire·5 days ago
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

GlobeNewsWire·5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARVN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Arvinas stock?

Arvinas (ARVN) has a market cap of $1.2B as of January 15, 2025.

What is the P/E ratio for Arvinas stock?

The price to earnings (P/E) ratio for Arvinas (ARVN) stock is 0 as of January 15, 2025.

Does Arvinas stock pay dividends?

No, Arvinas (ARVN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Arvinas dividend payment date?

Arvinas (ARVN) stock does not pay dividends to its shareholders.

What is the beta indicator for Arvinas?

Arvinas (ARVN) has a beta rating of 1.97. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.